logo
Share SHARE
FONT-SIZE Plus   Neg

Aeterna Zentaris' Phase3 Perifosine Trial Fails To Meet Primary Endpoint

Late-stage oncology drug development company Aeterna Zentaris Inc. (AEZS, AEZ.TO) said its Phase 3 trial evaluating perifosine in refractory advanced colorectal cancer patients failed to meet primary endpoint. Trading for Aeterna halted in early morning hours and shares are currently down more than 55 percent on the Nasdaq.

The focus of the X-PECT study was improvement of overall survival with perifosine in comparison with capecitabine + placebo. The trial involved 468 patients in 65 sites in the U.S and the study was conducted by the Company's North American licensee partner, Keryx Biopharmaceuticals, Inc. (KERX).

Aeterna Zentaris said it is very disappointed that the trial result. The company will continue further data analyses in collaboration with our licensee partners, in order to determine the future development strategy for perifosine.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Gambling resorts operator Wynn Resorts Ltd. (WYNN), has again postponed the opening of its Wynn Palace casino resort in Macau to August. The opening of the $4 billion hotel project in Macau, the gambling hub in China, was initially planned on March 25, but was later dropped due to construction delays.... PepsiCo Inc., (PEP) Monday confirmed that it would bring back the Diet Pepsi with aspartame in the US stores in September, one of the latest efforts by the beverage giant to boost its slowing sales. The company said it would continue to sell sucralose-sweetened Diet Pepsi, which was launched last... Burger giant Wendy's Co. (WEN) Monday announced its entry in to the Brazilian market through a joint venture with affiliates of Sao Paolo-based Infinity Services and Starboard, one of Wendy's largest U.S. franchisees and a subsidiary of the fast-food company. Wendy's Brazil plans to hold the grand...
comments powered by Disqus
Follow RTT